| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 0 | 0 | 0 | 0 | - | - | - | - | - | - |
| Total Income - EUR | 0 | 405 | 0 | 0 | - | - | - | - | - | - |
| Total Expenses - EUR | 208 | 290 | 1.625 | 75.325 | - | - | - | - | - | - |
| Gross Profit/Loss - EUR | -208 | 115 | -1.625 | -75.325 | - | - | - | - | - | - |
| Net Profit/Loss - EUR | -208 | 103 | -1.625 | -75.325 | - | - | - | - | - | - |
| Employees | 0 | 0 | 0 | 1 | - | - | - | - | - | - |
Check the financial reports for the company - Imedica Laboratories S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 180 | 0 | 0 | 1.385 | - | - | - | - | - | - |
| Current Assets | 9.860 | 9.635 | 59.159 | 32.998 | - | - | - | - | - | - |
| Inventories | 0 | 0 | 0 | 0 | - | - | - | - | - | - |
| Receivables | 9.536 | 9.427 | 9.722 | 31.987 | - | - | - | - | - | - |
| Cash | 324 | 209 | 49.436 | 1.012 | - | - | - | - | - | - |
| Shareholders Funds | -2.343 | -2.217 | -3.804 | -79.060 | - | - | - | - | - | - |
| Social Capital | 19.775 | 19.573 | 19.242 | 18.889 | - | - | - | - | - | - |
| Debts | 12.384 | 11.852 | 65.297 | 121.342 | - | - | - | - | - | - |
| Income in Advance | 0 | 0 | 0 | 0 | - | - | - | - | - | - |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "7219 - 7219" | |||||||||
| CAEN Financial Year |
7219
|
|||||||||
Comments - Imedica Laboratories S.r.l.